By measuring CD57+ T cells in the tumor immune microenvironment after treatment, the study found that combination therapy mobilized populations of both CD57-expressing CD8 and CD4 effector memory T cells from the bone marrow to the circulation, which was particularly effective in remodeling the immune contexture. This evidence concerns the gene B3GAT1 and neoplasm.